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Infused autograft absolute lymphocyte count is a prognostic factor for survival after autologous peripheral
hematopoietic stem cell transplantation (APHSCT) for diffuse large B cell lymphoma (DLBCL). CD14þ HLA-
DRlow/neg immunosuppressive monocytes affect tumor growth by suppressing host antitumor immunity.
Thus, we set out to investigate if the infused autograft lymphocyte to monocyte ratio (A-LMR), as a biomarker
of host immunity (ie, lymphocytes) and immunosuppression (ie, monocytes), affects survival after APHSCT.
From 1994 to 2012, 379 DLBCL patients who underwent APHSCT were studied. The 379 patients were
randomly divided into a training set (n ¼ 253) and a validation set (n ¼ 126). Receiver operating characteristic
and area under the curve identiﬁed an A-LMR 1 as the best cut-off value, which was validated by the k-fold
cross-validation in the training set. Multivariate analysis showed A-LMR to be an independent prognostic
factor for survival in the training set. Patients with an A-LMR  1.0 experienced superior overall survival (OS)
compared with patients with an A-LMR <1.0 (median OS: 167.2 versus 17.6 months; 5-year OS: 73% [95%
conﬁdence interval (CI), 63% to 80%] versus 30% [95% CI, 2% to 38%], P < .0001, respectively) in the training set.
In the validation set, an A-LMR  1 showed a median OS of 181.2 months versus 19.5 months for an A-LMR
<1, and 5-year OS rates of 67% (95% CI, 52% to 79%) versus 35% (95% CI, 25% to 47%), P < .0001, respectively.
The A-LMR provides a platform to engineer immunocompetent autograft to improve clinical outcomes in
DLBCL patients undergoing APHSCT.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Infused autograft absolute lymphocyte count (A-ALC)
.5  109 cells/kg is a prognostic factor for survival after
autologous peripheral hematopoietic stem cell trans-
plantation (APHSCT) for lymphoma [1] andmultiplemyeloma
[2,3]. However, some patients relapse after APHSCT, despite
infusing an A-ALC .5  109 cells/kg, whereas other patients
with an A-ALC <.5  109 cells/kg remain in complete
remission after APHSCT. Recent gene-expression proﬁling
studies in non-Hodgkin lymphoma have demonstrated that
gene expression by tumor-inﬁltrating myeloid-derived sup-
pressor cells predicts clinical outcomes [4,5]. Furthermore,
monocyte-derived cells may also provide trophic factors,
which directly promote the growth and survival of malignant
lymphocytes [6,7].
Two main subsets of myeloid-derived suppressor cells
(MDSCs) have been proposed in humans: the granulocytic andedgments on page 1811.
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ty for Blood and Marrow Transplantation.the monocytic MDSCs [8]. The human monocytic MDSCs
subset has been characterized asmonocytic CD14þ cellswith a
low level or lack of the antigen-presenting HLA-DR molecules
(CD14þHLA-DRlow/neg cells) [8]. Our group reported the pres-
ence of circulating immunosuppressive CD14þHLA-DRlow/neg
peripheral blood monocytes in patients with lymphoma
[9]. These circulating CD14þHLA-DRlow/neg monocytes are
recruitedand transformed into tumor-associatedmacrophages
by the tumor, affecting survival in cancer patients [10]. Stem
cell mobilization agents (ie, Neupogen [Amgen, Inc., Thousand
Oaks, CA]) have been implicated in the mobilization of mono-
cytes, inaddition to stemcells innormalvolunteers [11], aswell
as in patients undergoing APHSCT [12]. Thus, we studied the
impact of the autograft absolute lymphocyte tomonocyte ratio
(A-LMR) as a surrogate biomarker combining host immunity
(ie, A-ALC) and immunosuppression (ie, autograft absolute
monocyte count [A-AMC]), on clinical outcomes after APHSCT
in patients with diffuse large B cell lymphoma (DLBCL).
MATERIALS AND METHODS
Patient Population
To participate in the study, patients were required to be candidates for
APHSCT with the diagnosis of de novo DLBCL, have chemosensitive disease
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proceed with APHSCT (minimum of 2.0  106 CD34 cells/kg). Patients were
excluded if they failed tomobilize stem cells, required bonemarrow harvest,
were infused with both peripheral blood and bone marrow harvestederived
stem cells, participated in stem cell transplantation clinical trials, or had
either concomitant lymphoma histologies at diagnosis or transformed
lymphomas. No patients were lost to follow-up. From 1994 to 2012, 379
DLBCL patients qualiﬁed for the study. All patients gave written, informed
consent allowing the use of their medical records for medical research.
Approval for the retrospective review of these records was obtained from
the Mayo Clinic institutional review board and was in accordance with
federal regulations and the Declaration of Helsinki.
Endpoints
The primary endpoint of the study was to assess the impact of A-LMR on
overall survival (OS), progression-free survival (PFS), and lymphoma-
speciﬁc survival (LSS) from the time of APHSCT. The second endpoint was
to identify if A-ALC, A-AMC, and A-LMR directly affect the recovery of day 15
absolute lymphocyte count (ALC-15), day 15 absolute monocyte count
(AMC-15), and day 15 absolute lymphocyte tomonocyte ratio (LMR-15) after
APSHCT. The ALC-15, AMC-15, and LMR-15 were calculated from the com-
plete blood cell count [13] obtained at day 15 after APHSCT. The LMR-15 ratio
was calculated by dividing ALC-15 over AMC-15. The infused A-ALC for each
apheresed unit collection was calculated as follows: A-ALC ¼ % collection
lymphocytes (absoluteWBC/kg). In similar fashion, the infused A-AMC for
each apheresed unit collection was calculated as follows: A-AMC ¼ %
collection monocytes  (absolute WBC/kg). The A-LMR was then calculated
by dividing the A-ALC by the A-AMC.
Prognostic Factors
The following prognostic factors were evaluated in the study: interna-
tional prognostic index (IPI) [14] at diagnosis, age at diagnosis (60 versus
<60 years), lactate dehydrogenase (LDH) at diagnosis (>normal), perfor-
mance status at diagnosis (>1 versus 1), extranodal sites at diagnosis (>1
versus1), and stage at diagnosis (III/IV versus I/II), IPI at relapse [15], age at
relapse (>60 versus 60 years), extranodal sites at relapse (>1 versus 1),
LDH at relapse (abnormal), performance status at relapse (>1 versus1), and
stage at relapse (I/II versus III/IV), disease status before APHSCT (complete
remission [CR] versuspartial response), A-ALC, A-AMC, A-LMR,ALC-15, AMC-
15, LMR-15, and pretransplantation rituximab versus no rituximab [16].
Peripheral Blood Stem Cell (Autograft) Collections
The 3 different types of instruments used at our facility during the
period examined in this study were the COBE Spectra (Gambro BCT, Lake-
wood, CO), Baxter Amicus (Baxter Healthcare, Deerﬁeld, IL), and Fenwal
CS3000 (Baxter). All patients were collected using a single instrument type,
based on availability of the instrument on the day of collection. Patients
received granulocyte colonyestimulating factor (G-CSF) for mobilization at a
dose of 10 mg/kg daily for 5 to 7 consecutive days by subcutaneous injection.
After the peripheral blood CD34þ cell count was  10 cells/mL on G-CSF,
patients began daily apheresis until a minimum target of 2.0  106
CD34 cells/kg was reached. If the peripheral blood CD34 on day 4 on G-CSF
was less than 10 cells/mL, the addition of plerixafor (Sanoﬁ-Aventis,
Bridgewater, NJ) .24 mg/kg was allowed.
Conditioning Regimens
Conditioning regimens were as follows: 326 patients received BEAM
(BCNU [300 mg/m2] on day 6, etoposide [100 mg/m2] twice daily from
days 5 to 2, ARA-C [cytarabine] [100 mg/m2] twice daily from days 5
to 2, and melphalan (140 mg/m2) on day 1); 47 patients received BEAC
(BCNU [300 mg/m2] on day 6, etoposide [100 mg/m2] twice daily from
days 5 to 2, ARA-C [100 mg/m2] twice daily from days 5 to 2, and
cyclophosphamide (35 mg/kg) on day 1); and 6 patients received cyclo-
phosphamide (60 mg/m2  2) and total body irradiation (12 Gy).
Response and Survival
Response criteria were based on the guidelines from the International
Harmonization Project on Lymphoma [17]. OS was measured from the date
of transplantation to the date of death or last follow-up. PFS was deﬁned as
the time from transplantation to the time of progression, relapse, death, or
last follow-up. LSS was deﬁned as the time from transplantation to death as
a result of lymphoma.
Statistical Analysis
To assess the validity of the A-LMR as a prognostic factor for APHSCT in
DLBCL, patients were randomly divided into 2 groups. Two-thirds were
assigned to the training set (n ¼ 253) to develop the best cut-off value forA-LMR, and the remaining one-third were assigned to the validation set
(n ¼ 126) to assess the prognostic ability of A-LMR. OS, PFS, and LSS were
analyzed using the approach of Kaplan and Meier [18]. Differences between
survival curves were tested for statistical signiﬁcance using the 2-tailed log-
rank test. The Cox proportional hazard model [19] was used for the univari-
ate and multivariate analysis to evaluate the variables under the prognostic
factors section to assess their impact on post-APSCHT OS, PFS, and LSS times.
The choice of optimal cut-off for A-AMC, A-LMR, AMC-15, and LMR-15 to
assess survival was based on their utility as markers for the clinically relevant
binary outcome of death/survival, using the receiver operating characteristics
curves (ROC) and area under the curve (AUC). The binary clinical outcome
(death/survival) was established at 5 years after APHSCT. Patients were
classiﬁed as “alive/censored” when follow-up time was greater than 5 years
and “death” for patients known to have died before this time point [20]. A k-
fold cross-validationwith k values of 10 was performed to validate the results
of A-AMC, A-LMR, AMC-15, and LMR-15. Randomly chosen subsets containing
90% of the cohort were used for training, and the remaining 10% were left for
testing. The cross-validation process was then repeated 10 times. Based on
this analysis, cross-validation AUC by the ROC were produced, representing
the discriminating accuracy of A-AMC, A-LMR, AMC-15, and LMR-15 for the
binary clinical outcomes of death/survival. The cut-offs of A-ALC
.5 109 cells/kg and ALC-15 500 cells/mL used in this study were based on
our previous publications [1,21].
Chi-square tests and Fisher exact tests were used to determine
relationships between categorical variables as appropriate. The Wilcoxon
rank test was used to determine associations between continuous variables
and categories, and nonparametric tests were used to evaluate associations
for continuous variables. All P values represented were 2-sided and statis-
tical signiﬁcance was declared at P < .05.
RESULTS
Patients Characteristics
Themedian age at the timeof transplantation for this cohort
of 379 DLBCL patients was 58 years (range, 17 to 78 years). The
distribution of additional baseline characteristics for these
patients is presented in Table 1, based on the training set and
validation set. The median follow-up for the entire cohort was
27.1 months (range, 1 to 238.8 months) and for the living
patients (n ¼ 181), 77.4 months (range, 2.3 to 238.8 months).
The day 100 transplantation-related mortality for the cohort
was 2% (8 of 379). Onehundred andﬁfty-nine patients dieddue
to relapse/progression of lymphoma. Thirty-one patients died
of unrelated lymphoma causes, excluding the 8 patients who
died in the ﬁrst 100 days after APHSCT.
Cut-off Values for ALC-15, AMC-15, and ALC-15 to AMC-15
Ratio for Survival Analysis
ROC curves and AUC were used to determine the optimal
cut-off points for A-LMR, A-AMC, AMC-15, and LMR-15,
based on their utility as markers for the clinical binary
outcome of death/survival in the training set. The A-LMR 1
had an AUC of .73 (95% conﬁdence interval [CI], .55 to .91)
with a sensitivity of 73% (95% CI, 68% to 78%) and speciﬁcity
of 68% (95% CI, 62% to 74%), P < .04 (Figure 1A). The A-AMC
<.5109 cells/kg had an AUC of .63 (95% CI, .57 to .69) with a
sensitivity of 63% (95% CI, 57% to 69%) and speciﬁcity of 70%
(95% CI, 64% to 76%), P < .04. The AMC-15  600 cells/mL had
an AUC of .66 (95% CI, .61 to .74) with a sensitivity of 71% (95%
CI, 65% to 77%) and speciﬁcity of 67% (95% CI, 54% to 66%), P<
.0001. The LMR-15  1 had an AUC of .84 (95% CI, .81 to .87)
with a sensitivity of 80% (95% CI, 75% to 85%) and a speciﬁcity
of 79% (95% CI, 74% to 83%), P < .0001. An internal validation
of A-LMR, A-AMC, AMC-15, and LMR-15 performances as
markers for the clinical binary outcomes of death/survival
was performed using k-fold cross-validation with k ¼ 10. We
obtained an average AUC of .73 (95% CI, .67 to .80) over the 10
validation sets for A-LMR with a standard deviation of  .02.
In similar fashion, we obtained an average AUC for A-AMC of
.62 (95% CI, .56 to .68); for AMC-15, of .67 (95% CI, .59 to .75);
and for LMR-15, of .83 (95% CI, .78 to .89). We report the ROC
Table 1
Baseline Characteristics in the Training Set and Validation Set
Variable Training Set
n ¼ 253
Validation Set
n ¼ 126
P Value*
A-LMR  1
(n ¼ 126)
A-LMR < 1
(n ¼ 127)
P Value A-LMR  1
(n ¼ 52)
A-LMR < 1
(n ¼ 74)
P Value
At diagnosis
Age, median (range), yr 58 (19-72) 5 (23-76) .70 52 (21-76) 60 (17-74) .20 <.01
Gender .80 .50 .50
Male 78 (62%) 77 (61%) 36 (69%) 46 (62%)
Female 48 (38%) 50 (39%) 16 (31%) 28 (38%)
Extra-nodal .70 .30 .50
0 73 (58%) 76 (60%) 34 (65%) 46 (62%)
1 38 (30%) 33 (26%) 11 (21%) 15 (20%)
2 13 (10%) 14 (11%) 7 (14%) 10 (14%)
3 2 (2%) 3 (2%) 0 (0%) 3 (4%)
4 0 (0%) 1 (1%)
LDH, median (range), U/L 211 (80-2400) 281 (60-2250) .20 300 (151-1460) 264 (139-1812) .20 .20
PS .10 .10 .20
0 24 (19%) 25 (20%) 13 (25%) 14 (19%)
1 101 (80%) 96 (75%) 37 (71%) 57 (77%)
2 1 (1%) 6 (5%) 0 (0%) 3 (4%)
3 2 (4%) 0 (0%)
Stage .70 .50 <.04
I 13 (10%) 18 (14%) 1 (2%) 5 (7%)
II 21 (17%) 21 (16%) 5 (10%) 10 (13%)
III 24 (19%) 25 (20%) 12 (23%) 17 (23%)
IV 68 (54%) 63 (50%) 34 (65%) 42 (57%)
IPI risk factors
Age, yr .70 .90 <.01
>60 53 (42%) 56 (44%) 15 (29%) 23 (30%)
60 73 (58%) 71 (56%) 37 (71%) 52 (70%)
Extra-nodal .70 .60 .50
>1 15 (12%) 18 (14%) 7 (13%) 13 (18%)
1 111 (88%) 109 (86%) 45 (82%) 61 (82%)
LDH (U/L) .10 .40 .10
Abnormal 56 (44%) 69 (54%) 33 (63%) 40 (54%)
Normal 70 (56%) 58 (46%) 19 (37%) 34 (46%)
PS .10 .90 .50
>1 1 (1%) 6 (5%) 2 (4%) 3 (4%)
1 125 (99%) 121 (95%) 50 (96%) 71 (96%)
Stage .60 .20 <.01
I/II 56 (44%) 69 (54%) 33 (63%) 40 (54%)
III/IV 70 (56%) 58 (46%) 19 (37%) 37 (46%)
IPI score .50 .50 .70
0 13 (10%) 15 (12%) 4 (8%) 8 (11%)
1 39 (31%) 31 (24%) 15 (29%) 16 (22%)
2 44 (35%) 48 (38%) 19 (36%) 28 (28%)
3 22 (18%) 29 (23%) 11 (21%) 21 (28%)
4 8 (6%) 4 (3%) 3 (6%) 1 (1%)
IPI index .40 .70 .40
>2 74 (59%) 81 (64%) 33 (63%) 50 (68%)
2 52 (41%) 46 (36%) 19 (37%) 24 (32%)
At relapse
Age, median (range), yr 60 (19-79) 60 (23-76) .90 56 (21-76) 54 (18-74) .2 <.008
Extra-nodal .30 <.009 .30
0 23 (18%) 15 (12%) 10 (19%) 13 (17%)
1 88 (70%) 97 (76%) 40 (77%) 43 (58%)
2 15 (12%) 15 (12%) 2 (4%) 17 (25%)
3 0 (0%) 1 (2%)
PS .20 .90 .60
0 23 (18%) 15 (12%) 10 (19%) 13 (917%)
1 88 (70%) 97 (76%) 40 (77%) 43 (58%)
2 9 (7%) 14 (11%) 3 (5%) 5 (7%)
LDH (U/L) 225 (75-1899) 230 (112-1065) .10 240 (125-492) 238 (136-1102) .9 .20
Stage .90 .10 .20
I 17 (14%) 19 (15%) 13 (25%) 9 (12%)
II 33 (26%) 30 (24%) 8 (15%) 21 (28%)
III 20 (16%) 23 (18%) 15 (29%) 16 (22%)
IV 56 (44%) 65 (43%) 16 (31%) 28 (38%)
IPI risk factors
Age, yr .60 .60 <.004
>60 61 (48%) 57 (45%) 18 (35%) 21 (28%)
60 65 (52%) 70 (55%) 34 (65%) 53 (72%)
Extra-nodal .90 <.002 .30
>1 15 (12%) 15 (12%) 2 (4%) 18 (24%)
(Continued on next page)
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Table 1
(continued)
Variable Training Set
n ¼ 253
Validation Set
n ¼ 126
P Value*
A-LMR  1
(n ¼ 126)
A-LMR < 1
(n ¼ 127)
P Value A-LMR  1
(n ¼ 52)
A-LMR < 1
(n ¼ 74)
P Value
1 111 (85%) 112 (88%) 50 (96%) 56 (76%)
LDH (U/L) <.01 .90 .08
Abnormal 47 (37%) 68 (54%) 29 (36%) 41 (55%)
Normal 79 (63%) 59 (46%) 23 (44%) 35 (45%)
PS .40 .80 .40
>1 9 (7%) 14 (11%) 3 (6%) 5 (97%)
1 117 (93%) 113 (89%) 49 (94%) 69 (93%)
Stage .90 .90 .80
I/II 50 (40%) 49 (39%) 31 (60%) 44 (59%)
III/IV 76 (60%) 78 (61%) 21 (40%) 30 (41%)
IPI score .30 .08 .10
0 18 (14%) 16 (13%) 10 (19%) 16 (22%)
1 43 (34%) 38 (30%) 12 (23%) 17 (23%)
2 38 (30%) 33 (26%) 22 (42%) 22 (30%)
3 18 (14%) 32 (25%) 8 (16%) 11 (15%)
4 9 (8%) 7 (5%) 0 (0%) 6 (8%)
5 0 (0%) 1 (1%) 0 (0%) 2 (2%)
IPI index .07 .20 .30
>2 27 (21%) 40 (32%) 8 (15%) 19 (26%)
2 99 (79%) 87 (68%) 44 (85%) 55 (74%)
Before transplantation
Pretransplantation rituximab .50 .90 .90
No 44 (35%) 49 (39%) 19 (37%) 26 (35%)
Yes 82 (65%) 78 (61%) 33 (63%) 48 (65%)
Pretransplantation treatments, n .60 .20 .10
2 115 (91%) 117 (92%) 47 (90%) 50 (81%)
3 10 (8%) 9 (7%) 5 (10%) 13 (18%)
4 1 (1%) 1 (91%) 0 (0%) 1 (1%)
Clinical status before transplantation .06 .30 .30
CR 52 (41%) 37 (30%) 19 (37%) 23 (31%)
PR 74 (59%) 90 (70%) 33 (63%) 51 (69%)
At transplantation
Age, median (range), yr 60 (24-78) 61 (20-77) .50 57 (19-76) 54 (21-76) .10 <.02
Plerixafor .90 .70 .30
Yes 26 (20%) 26 (20%) 9 (17%) 11 (15%)
No 100 (80%) 101 (80%) 43 (83%) 63 (85%)
Conditioning regimens <.02 .07 .60
CTX/TBI 2 (2%) 3 (92%) 0 (0%) 1 (1%)
BEAC 9 (8%) 23 (18%) 10 (19%) 5 (7%)
BEAM 115 (91%) 101 (80%) 42 (81%) 68 (92%)
Infused CD34 4.5 (2.05-14.85) 4.2 (2.11-11.06) .40 4.6 (2.12-11.37) 4.5 (2.03-11.52) .90 .60
A-ALC, median (range) .78 (.21-2.18) .39 (.03-1.42) <.0001 .80 (.32-2.61) .39 (.04-2.01) <.0001 .80
A-AMC, median (range) .47 (.01-1.38) .76 (.14-1.97) <.0001 .49 (.11-1.90) .75 (.24-2.41) <.0001 .10
ALC-15, median (range) .67 (.08-3.54) .38 (.01-1.68) <.0001 .77 (.09-2.64) .39 (.05-2.14) <.0001 .70
AMC-15, median (range) .48 (.01-1.80) .78 (.03-2.83) .53 (.01-2.50) .74 (.04-2.60) <.0001 .10
LMR-15 1.37 (.25-31) .57 (.02-9) <.0001 .39 (.13-71) .59 (.04-3.38) <.0001 .20
U/L indicates upper limit; PS, performance status; PR, partial response; CTX, cyclophosphamide; TBI, total body irradiation; BEAC, BCNU, etoposide, ARA-C, and
cyclophosphamide; BEAM, BCNU, etoposide, ARA-C, and melphalan.
Data presented are n (%) unless otherwise indicated.
* Difference between the training and validation set.
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collecting the A-LMR, A-AMC, AMC-15, and LMR-15 obtained
on each fold. For A-LMR, the cross-validation ROC (Figure 1B)
showed an AUC of .73 (95% CI, .50 to .92); for A-AMC, an AUC
of .63 (95% CI, .56 to .71); for AMC-15, an AUC of .66 (95% CI,
.60 to .72); and for LMR-15, an AUC of .84 (95% CI, .80 to .88).
The similar AUC from the empirical ROC and the cross-
validation ROC support the use of A-LMR 1, A-AMC
.5109 cells/kg, AMC-15 600 cells/mL, and LMR-151 as
the cut-off values as markers of the binary clinical outcome
of death/survival.
Correlation between A-AMC and AMC-15 and between
A-LMR and LMR-15 in the Training Set
We previously reported that ALC-15 recovery after
APHSCT depended on the infused A-ALC. In this cohort ofpatients, a strong positive correlation between A-ALC and
ALC-15 was observed in the training set (R ¼ .8, P < .0001)
and validated in the validation set (R ¼ .6, P < .0001). The
infusion of CD34 cells did not correlate with ALC-15 (R ¼ .1,
P ¼ .20 in the training set and R ¼ .2, P ¼ .10 in the validation
set). Therefore, we investigated if the A-AMC affects AMC-15
recovery as well as A-LMR directly affect LMR-15 after
APHSCT. We identiﬁed a positive correlation between the
infused A-AMC and AMC-15 (R¼ .8, P< .0001) in the training
set and (R ¼ .8, P < .0001) in the validation set. We also
identiﬁed a positive correlation between A-LMR and LMR-15
(R¼ .7, P< .0001) in the training set (Figure 2A) and (R¼ .6, P
< .0001) in the validation set (Figure 2B). Infused CD34 did
not correlate with AMC-15 (P ¼ .10 in the training set and
P ¼ .60 in the validation set) and LMR-15 (P ¼ .60 in the
training set and P ¼ .10 in the validation set).
Figure 1. (A) Receiver operating characteristics curves (ROC) and area under the curve (AUC) for autograft lymphocyte to monocyte ratio (A-LMR) in the training set.
(B) K-fold cross-validation ROC and AUC for A-LMR in the training set.
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Using the univariate Cox regression analysis, the
following variables were predictors for OS, PFS, and LSS: LDH
at diagnosis, LDH at relapse, stage at relapse, IPI at diagnosis,
IPI at relapse, CR before transplantation, A-ALC, ALC-15,
A-AMC, AMC-15, A-LMR, and LMR-15 (Table 2). Extranodal
sites at relapse was a predictor for OS and PFS (Table 2).
Multivariate analysis identiﬁed the following predictors for
survival: A-ALC (OS, PFS, LSS), A-AMC (OS, PFS, LSS), A-LMR
(OS, PFS, LSS), CR before transplantation (OS, PFS), LDH at
relapse (PFS, LSS), and stage at relapse (PFS) (Table 3). To
avoid the problem of colinearity due the strong positive
correlation between A-ALC and ALC-15, between A-AMC and
AMC-15, and between A-LMR and LMR-15, we substituted
ALC-15 for A-ALC, AMC-15 for A-AMC, and LMR-15 for A-LMR
and tested them against the other predictors (LDH at
diagnosis, LDH at relapse, stage at relapse, IPI at diagnosis, IPI
at relapse, and CR before transplantation) in the multivariate
analysis. ALC-15 remained an independent predictor for OS
(hazard ratio [HR], .49; 95% CI, .30 to .80; P < .004), for PFS
(HR, .53; 95% CI, .36 to .79; P< .002), and for LSS (HR, .44; 95%
CI, .24 to .79; P < .005); A-AMC for OS (HR, .40; 95% CI, .20 to
.80; P < .01), for PFS (HR, .61; 95% CI, .37 to .97; P < .04), and
for LSS (HR, .29; 95% CI, .13 to .66; P < .003); and LMR- 15 for
OS (HR, .23; 95% CI, .11 to .44; P< .0001), for PFS (HR, .24; 95%
CI, .15 to .40; P < .0001), and for LSS (HR, .12; 95% CI, .05 to
.28; P < .0001).Figure 2. (A) Scatter plot of autograft lymphocyte to monocyte ratio (A-LMR) and l
hematopoietic stem cell transplantation in the training set. (B) Scatter plot of autograf
day 15 (LMR-15) after autologous peripheral hematopoietic stem cell transplantationThe absolute monocyte count at diagnosis (AMC-D) has
been also reported to be a predictor for survival in DLBCL. In
the univariate analysis, we conﬁrmed that AMC-D was a
predictor for OS (HR, .55; 95% CI, .35 to .67; P < .0001), PFS
(HR, .65; 95% CI, .41 to .91; P < .01), and LSS (HR, .41; 95% CI,
.29 to .63; P < .0002). When we compared AMC-D against
A-LMR in the multivariate analysis, A-LMR remained an in-
dependent predictor compared with AMC-D for OS (HR, .52;
95% CI, .31 to .87; P< .01), for PFS (HR, .61; 95% CI, .37 to .67; P
< .03), and for LSS (HR, .34; 95% CI, .18 to .63; P < .0004).
Survival Outcomes Based on A-LMR
Using the cut-off value of 1.0 for the A-LMR obtained from
the empiric ROC and subsequently validated by k-fold cross-
validation in the training set, we tested A-LMR1 for OS, PFS,
and LSS. We observed that patients infused with an A-LMR
1 compared with patients infused with an A-LMR <1
experienced superior OS (Figure 3A) and PFS (Figure 3B) in
the training set (median OS was 167.2 months versus
17.6 months; 5-year OS, 73% [95% CI, 63% to 80%] versus 30%
[95% CI, 22% to 38%], respectively; P < .0001; median PFS of
152.9 months versus 6.6 months; 5-year PFS of 67% [95% CI,
57% to 75%] versus 26% [95% CI, 18% to 34%], respectively; P <
.0001). The superior OS and PFS observed in the group with
an A-LMR 1 versus the group with an A-LMR <1 was
further validated in the validation set (median OS was
181.2 months versus 19.5 months; 5-year OS of 67% [95% CI,ymphocyte to monocyte ratio at day 15 (LMR-15) after autologous peripheral
t lymphocyte to monocyte ratio (A-LMR) and lymphocyte to monocyte ratio at
in the validation set.
Table 2
Univariate Analysis for OS, PFS, and LSS in the Training Set
Variable OS PFS LSS
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Age-D > 60 1.20 (.85-1.70) .30 1.10 (.77-1.48) .70 1.01 (.69-1.51) .90
Age-R > 60 1.14 (.80-1.61) .05 1.15 (.82-1.59) .40 1.02 (.69-1.52) .90
LDH-D (abnormal) 1.69 (1.91-2.43) <.003 1.74 (1.25-2.44) <.01 1.84 (1.24-2.76) <.002
LDH-R (abnormal) 2.58 (1.87-3.72) <.0001 2.61 (1.82-3.76) <.0001 2.53 (1.71-3.82) <.0001
Extra-nodal-D > 1 1.24 (.72-2.02) .40 1.18 (.70-1.86) .50 1.44 (.82-2.40) .20
Extra-nodal-R > 1 1.79 (1.10-2.78) <.02 1.58 (1.01-2.40) <.05 1.69 (.92-2.78) .06
PS-D > 1 1.33 (.41-3.15) .60 2.03 (.86-1.03) .10 1.24 (.31-3.31) .70
PS-R > 1 2.91 (1.75-4.60) <.0001 2.36 (1.43-3.71) <.001 2.90 (1.63-4.83) <.0006
Stage-D (III/IV) 1.20 (.82-1.80) .30 1.24 (.87-1.80) .20 1.30 (.85-2.08) .20
Stage-R (III/IV) 2.18 (1.49-3.25) <.0001 2.14 (1.50-3.10) <.0001 2.14 (1.40-3.37) <.0004
IPI-D > 2 1.65 (1.14-2.45) <.008 1.75 (1.23-2.53) <.002 1.74 (1.14-2.71) <.009
IPI-R > 2 2.65 (1.85-3.79) <.0001 2.44 (1.73-3.42) <.0001 2.38 (1.59-3.55) <.0001
CR before transplantation .37 (.20-.64) <.0002 .41 (.23-.67) <.0002 .40 (.20-.73) <.002
Rituximab before transplantation .77 (.54-1.12) .20 .85 (.60-1.20) .40 .77 (.52-1.16) .20
A-ALC  .5  109/kg .37 (.25-.52) <.0001 .43 (.31-.60) <.0001 .29 (.19-.43) <.0001
A-AMC  .5  109/kg .58 (.39-.83) <.003 .59 (.41-.83) <.002 .51 (.32-.77) <.001
A-LMR  1 .29 (.20-.43) <.0001 .32 (.22-.45) <.0001 .18 (.10-.28) <.0001
ALC-15  500 cells/mL .30 (.20-.42) <.0001 .36 (.25-.50) <.0001 .25 (.16-.34) <.0001
AMC-15  600 cells/mL .36 (.24-.52) <.0001 .37 (.27-.51) <.0001 .30 (.19-.45) <.0001
LMR-15  1 .13 (.08-.20) <.0001 .14 (.10-.21) <.0001 .07 (.03-.17) <.0001
D indicates at diagnosis; R, at relapse.
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.0001; median PFS of 181.2 months versus 10.1 months; 5-
year PFS of 65% [95% CI, 51% to 77%] versus 27% [95% CI,
18% to 39%], respectively; P< .0001) (Figure 3D,E). Because of
the long-term follow-up of 238.8 months in a group with a
median age of 58 years, we analyzed the LSS to evaluate the
direct impact of A-LMR on lymphoma survival, as patients in
this cohort eventually died of other physical conditions not
related to their APHSCT complications or lymphoma. In the
training set, we observed superior LSS in patients with an A-
LMR 1 in comparison with patients with an A-LMR <1
(median LSS was not-reached versus 18.6 months, 5-year LSS
of 81% [95% CI, 72% to 88%] versus 33% [95% CI, 25% to 42%],
respectively; P < .0001) (Figure 3C). This observation was
validated in the validation set (median LSS was not-reached
versus 23.1 months, 5-year LSS of 71% [95% CI, 57% to 82%]
versus 44% [95% CI, 32% to 56%], respectively, P < .0001)
(Figure 3F).
DISCUSSION
A-ALC has been reported to be a prognostic factor for
survival after APHSCT [1-3], suggesting that host immunity
affects clinical outcomes of patients treated with APHSCT.
However, relapses have been reported in patients with
infused A-ALC .5  109 cells/kg and long-lasting CR mayTable 3
Multivariate Analysis for OS, PFS, and LSS in the Training Set
Variable OS PFS
HR (95% CI) P Value HR
LDH-D (abnormal) 1.44 (.86-2.45) .20 1.2
LDH-R (abnormal) 1.43 (.78-2.59) .20 1.4
Extra-nodal-R > 1 1.34 (.66-2.87) .40 1.2
PS-R > 1 1.59 (.95-2.69) .08 1.9
Stage-R (III/IV) 1.54 (.90-2.69) .10 1.5
IPI-D > 2 1.03 (.59-1.80) .90 1.0
IPI-R > 2 1.56 (.56-2.37) .70 1.2
CR before transplantation .50 (.27-.88) <.02 .6
A-ALC  .5  109/kg .56 (.36-.96) <.03 .6
A-AMC  .5  109/kg .48 (.25-.95) <.04 .5
A-LMR  1 .53 (.33-.87) <.01 .5occur in patients with infused low A-ALC < .5  109 cells/kg
[1]. Thus, we set out to investigate what other factors might
counteract the superior clinical outcomes produced by A-ALC
after APHSCT. Recent studies have shown the immunosup-
pressive and tumor growth effects of CD14þ HLA-DRlow/neg
immunosuppressive monocytes. Because the A-AMC can be
easily obtained from each apheresed unit, we combined A-
ALC and A-AMC, as representative biomarkers of host im-
munity and immunosuppression, to study clinical outcomes
after APHSCT in patients with DLBCL.
As in our previous publications, this study continues to
show better clinical outcomes after APHSCT in DLBCL pa-
tients infused with an A-ALC .5  109 cells/kg. However,
patients infused with an A-AMC >.5  109 cells/kg also
experienced inferior clinical outcomes. Combining both
biomarkers, patients with an A-LMR  1 showed superior
survival compared with those with an A-LMR <1. This
ﬁnding was subsequently supported in a validation set. In
multivariate analysis, it was revealed that A-LMR was an
independent predictor for survival after APHSCT in the
DLBCL.
We previously reported ALC-15 to be a prognostic factor
for survival after APHSCT [21-25], which was conﬁrmed by
independent groups [26,27]. This initial observation led us to
investigate the source of ALC-15 recovery. We subsequentlyLSS
(95% CI) P Value HR (95% CI) P Value
5 (.85-1.85) .30 1.35 (.75-2.45) .30
9 (1.03-2.16) <.04 2.00 (1.40-3.47) <.02
3 (.73-2.10) .40
3 (.69-2.02) .50 1.47 (.81-2.71) .20
1 (1.08-2.30) <.05 1.57 (.85-2.99) .10
3 (.67-1.59) .90 1.09 (.58-2.03) .80
6 (.75-2.12) .40 1.37 (.64-2.98) .40
1 (.39-.92) <.02 .60 (.29-1.14) .10
5 (.44-.96) <.03 .37 (.17-.80) <.01
9 (.38-.92) <.02 .53 (.29-.97) <.04
7 (.38-.85) <.006 .39 (.19-.78) <.008
Figure 3. (A) Shows OS in the training set, (B) shows PFS in the training set, and (C) shows LSS in the training set. (D) Shows OS in the validation set, (E) shows PFS in
the validation set, and (F) shows LSS in the validation set.
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[1,2], suggesting that immune effectors cells collected in the
autograft directly affect immune recovery and survival after
APHSCT. Thus, we investigated if the collected A-AMC and A-
LMR correlated with AMC-15 and LMR-15. None of the pa-
tients in this study had any manipulation of their collected
and infused autograft. We identiﬁed a strong positive cor-
relation between the A-AMC and AMC-15, as well as A-LMR
and LMR-15. No correlation was identiﬁed between CD34
and ALC-15, AMC-15, and LMR-15.
There are several possible mechanisms explaining why an
A-LMR< 1was associatedwith inferior survival after APHSCT
by the infusion of high numbers of A-AMC. First, mobilized
and collected monocytes have been shown to produce
immunosuppressive cytokines (ie, IL-1b, IL-6, IL-10, TNF-a,
transforming growth factor-b) dampening the host immune
response [8,28,29]. Second, during cell-to-cell interaction,
CD14þHLA-DRlow/neg immunosuppressivemonocytesdisrupt
the binding of speciﬁc peptide-major histocompatibility
complex dimers to CD8þ Tcells through nitration of tyrosinesby the production of peroxynitrite, rendering CD8þ T cells
unable to respond to speciﬁc peptides [30]. In allogeneic stem
cell transplantation, downregulation of the expression of
CD3z-chain has been reported by indoleamine 2, 3-
dioxygenase produced by CD14þHLA-DRlow/neg cells. Block-
ing indoleamine 2, 3-dioxygenase restored the CD3z-chain
expression, as well as increased production of interferon-Y,
thus T cell activation [28]. No studies are available in APHSCT,
but it is reasonable to hypothesize a similar process of T cell
immunosuppression by the A-AMC could occur. Third,
induction of regulatory T cells may be responsible. In a recent
study in multiple myeloma patients mobilized with high-
dose cyclophosphamide and G-CSF for APHSCT, researchers
identiﬁed high levels in the autograft of CD4þ CD25high
regulatory T cells expressing high levels of Forkhead box
P3 (FOXP3), cytotoxic-T-lymphocyte-associated protein 4,
cytotoxic-T-lymphocyte-associated protein 4 (CTLA-4),
and glucocorticoid-induced tumor-necrosis-factor-receptor-
related protein (GITR), and displaying in vitro suppressive
properties [31]. Fourth, upregulation of the death receptor Fas
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killer (NK) cells function is also possible. In vitro studies have
shown that removal of granulocyte-macrophage colony-
stimulating factoremobilized or G-CSFemobilized CD14þ
monocytes from the autograft increases NK cell function [33].
This is an important ﬁnding, as we previously published in a
prospective study that NK cells are the main lymphocyte
subset in the ALC-15 affecting survival after APHSCT [34].
Further studies are warranted to measure the CD14þ HLA-
DRlow/neg immunosuppressive monocytes from the mono-
cytic component collected in autografts to assess their impact
on clinical outcomes.
To minimize the inherent biases of a retrospective
study, such as selection bias and confounding factors,
several steps were taken. In regard to selection bias, we
included only patients with the unifying diagnosis of
DLBCL to have a homogenous group. In addition, patients
who received bone marrow harvest or combination of bone
marrow harvest/peripheral blood stem cells were
excluded. Only patients who received infused peripheral
blood stem cells mobilized by G-CSF with or without
plerixafor were included. Patients who participated in
stem cell transplantation clinical trials were also excluded.
Furthermore, patients were randomly divided into a
training set and validation set to validate our ﬁndings. In
regard to confounding factors, by the multivariate analysis,
A-LMR remained an independent prognostic factor when
compared with currently known prognostic factors for
DLBCL patients undergoing APHSCT.
The strengths of the study include long-term follow-up of
a uniform group of patients with DLBCL treated consecu-
tively at a single institution. This study expands on the pre-
vious publications regarding A-ALC/ALC-15 by highlighting
the importance of the interaction between host immunity
and immunosuppression, using the simple biomarkers of
A-ALC and A-AMC combined with the prognostic factor of
A-LMR. Finally, the association between A-LMR and LMR-15,
as well as A-AMC and AMC-15, provides a rationale to
develop clinical translational interventions to engineer
immunocompetent autograft with direct impact on immune
recovery and survival after APHSCT. In regard to the
collection of monocytes, G-SCF has been reported tomobilize
and upregulate peripheral blood monocytes not only in pa-
tients undergoing APHSCT but also in normal donors for
allogeneic stem cell transplantation. In allogeneic stem cell
transplantation, the immunosuppressive effect of CD14þ
HLA-DRlow/neg monocytes could be exploited to treat graft-
versus-host disease. Even the use of plerixafor has been
associated in the mobilization of high levels of monocytes in
the peripheral blood [35]. Only 18% of patients received
plerixafor in our cohort, rendering not enough events to
perform meaningful statistical analysis to compare mono-
cyte mobilization between patients who were mobilized
only by G-CSF and those who were mobilized by G-CSF with
plerixafor. Therefore, more targeted stem cell mobilization
agents to mobilize stem cells, immune effector cells, and
minimize collection of CD14þ HLA-DRlow/neg immunosup-
pressive monocytes might be a new avenue for a more
immunocompetent autograft. Another option to reduce the
infusion of CD14þ immunosuppressive monocytes is to
perform an autograft monocytic depletion, using a CD14þ
column to remove CD14þHLA-DRlow/neg immunosuppressive
monocytes from the autograft product.
In conclusion, if reproducible, the A-LMR has the potential
to be an easily obtainable and universally applied biomarkerto individually engineer immunocompetent autograft to
improve clinical outcomes after APHSCT in DLBCL.
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